Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03022786 · ClinicalTrials.gov registry record · NA
Improving Value of Care for Patients With Severe Stasis Dermatitis
A NA study of Stasis Dermatitis, sponsored by University Hospitals Cleveland Medical Center.
- Completed
- Registry status
- NA
- Development phase
- 28
- Enrollment target
- 1
- Study location
NCT03022786: Completed NA study of Stasis Dermatitis, sponsored by University Hospitals Cleveland Medical Center.
NCT03022786 is a NA study of Stasis Dermatitis that has completed, run by University Hospitals Cleveland Medical Center. The registered enrollment target is 28 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03022786, a NA study of Stasis Dermatitis, has completed, sponsored by University Hospitals Cleveland Medical Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 28 participants
- Enrollment target
- 1
- Study location
Study Summary
Explore the unmet needs of patients admitted to the hospital for severely inflamed skin of the lower legs, often described as 'bilateral cellulitis". These patients usually have intractable lower extremity edema, stasis dermatitis and sometimes allergic contact dermatitis rather than an infectious process; readmission is common. Investigators will create patient and provider education materials to align dermatological, home health, and other resources and measure reduction in hospital re-admission rate and length of stay.
Primary Outcome
Feb-Sept in both years
Conditions Studied
Interventions
- OTHER Order set
- OTHER Motivational Interviewing training for home health aides
- OTHER Tools & Education
Study Locations (1)
Ohio
- University Hospitals - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2017-01 |
| Est. Completion | 2018-12 |
| Phase | NA |
What the finished NCT03022786 record still lists
NCT03022786 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 28 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Stasis Dermatitis appearing as the primary indexed condition, and to 3 interventions - of which Order set is the first listed.
NCT03022786 reports a single indexed study location in Ohio.
Frequently Asked Questions
What is clinical trial NCT03022786 about?
NCT03022786 is a clinical study titled "Improving Value of Care for Patients With Severe Stasis Dermatitis". Explore the unmet needs of patients admitted to the hospital for severely inflamed skin of the lower legs, often described as 'bilateral cellulitis". These patients usually have intractable lower extremity edema, stasis dermatitis and sometimes allergic contact dermatitis rather than an infectious p...
What is the current status of trial NCT03022786?
This trial is currently completed. It is a NA study. The enrollment target is 28 participants. The study started on 2017-01. Estimated completion is 2018-12.
What conditions does trial NCT03022786 study?
This clinical trial studies the following conditions: Stasis Dermatitis.
What interventions are being tested in trial NCT03022786?
The interventions under investigation include: Order set (OTHER), Motivational Interviewing training for home health aides (OTHER), Tools & Education (OTHER).
Who is sponsoring clinical trial NCT03022786?
This trial is sponsored by University Hospitals Cleveland Medical Center, which has 230 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03022786 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03022786's enrollment target sits among peer trials
28 1704th of 2000 higher than 293 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03471117 · 28 participants · Phase 4
Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients
- NCT03523975 · 28 participants · Phase 1
Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma
- NCT03608631 · 28 participants · Phase 1
iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation
- NCT03810651 · 28 participants · Early Phase 1
Pencil Beam Scanning in Patients With Renal Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia